Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis

Published:2020-04-13 Issue:2 Volume:183 Page:397-398
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Gisondi P.¹^ORCID,Virga C.¹,Piaserico S.²,Meneguzzo A.²,Odorici G.³^ORCID,Conti A.³^ORCID,Girolomoni G.¹

Affiliation:

1. Department of Medicine Section of Dermatology and Venereology University of Verona Verona Italy

2. Department of Medicine Section of Dermatology and Venereology University of Padua Padua Italy

3. Department of Head and Neck Surgery Section of Dermatology Azienda Ospedaliero Universitaria Policlinico di Modena Modena Italy

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19013

Reference8 articles.

1. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience

2. SB2: An Infliximab Biosimilar

3. Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

4. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

5. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching;BioDrugs;2024-03-23

2. Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies;Biologics;2023-04-27

3. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis;Journal of Dermatological Treatment;2023-01-19

4. Biosimilars approved for psoriasis treatment in Europe;PONS - medicinski casopis;2023

5. Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability;Therapeutic Innovation & Regulatory Science;2022-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3